araag2/HINT huggingface dataset:
Clinical trial NCT03000530 (phase 2, status: completed)
Conditions: major depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: sage-217, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant has a diagnosis of Major Depressive Disorder that has been present for at
             least a 4-week period as diagnosed by Structured Clinical Interview for DSM-IV Axis I
             Disorders (SCID-I)

        Exclusion Criteria:

          -  Participant has a history of suicide attempt

          -  Participant has a history of treatment-resistant depression, defined as persistent
             depressive symptoms despite treatment with adequate doses of antidepressants from two
             different classes for an adequate amount of time

          -  Participant has active psychosis

          -  Participant has a medical history of seizures

          -  Participant has a medical history of bipolar disorder, schizophrenia, and/or
             schizoaffective disorder
Clinical trial NCT03000569 (phase 2, status: completed)
Conditions: parkinson disease
ICD codes: G20
Drugs: sage-217, levodopa, antiparkinsonian agent(s)
SMILES: C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant has a diagnosis of idiopathic Parkinson's Disease (Hoehn and Yahr Stage 2
             or Stage 3) with a duration of less than 7 years prior to screening [Part A]

          -  Participant has a diagnosis of idiopathic Parkinson's Disease (Hoehn and Yahr Stage
             1-4, assessed during the "on" period) [Part B]

          -  Participant is on a stable dose (at least 1 month prior to baseline visit) of an
             antiparkinsonian agent and is willing to remain on this dose for the duration of the
             study

        Exclusion Criteria:

          -  Participant has early (Hoehn and Yahr Stage 1) or advanced (Hoehn and Yahr Stage 4 or
             Stage 5) Parkinson's Disease [Part A]

          -  Participant has advanced (Hoehn and Yahr Stage 5) Parkinson's Disease [Part B]

          -  Participant with presence of drug-induced parkinsonism, metabolic identified
             neurogenetic disorders, encephalitis, or other atypical Parkinsonian syndromes

          -  Participant with medical history of electroconvulsive therapy or stereotaxic brain
             surgery for Parkinson's Disease

          -  Participant with medical history of suicide attempt within 2 years of screening or
             current suicidal ideation

          -  Participant with medical history of impulse control disorder
Clinical trial NCT03001219 (phase 2, status: terminated)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: anti-tnf-alpha, methotrexate, placebo, ro7123520
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the trial was prematurely terminated due to a lack of efficacy of the investigational drug.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of adult-onset RA as defined by the ACR 2010 criteria, for at least 6 months
             before screening

          -  Moderately to severely active RA as defined by at least 4/28 tender joints and at
             least 4/28 swollen joints, and a DAS28 greater than or equal to (≥) 3.2

          -  For Part 2 only: Active synovitis and/or osteitis as determined by contrast-enhanced
             magnetic resonance imaging

          -  Participants must be taking stable dose of anti-TNF-alpha therapies

          -  Participants on stable oral glucocorticoids within 6 weeks of planned randomization

          -  Participants taking non-steroidal anti-inflammatory drugs (NSAIDs) intermittently (up
             to 2-3 times weekly) for short-term relief of pain and participants on regular NSAID
             use (on stable dose for ≥ 4 weeks)

        Exclusion Criteria:

          -  Parenteral glucocorticoids administration (intramuscular, IV) of ≥50 mg within 6 weeks
             or less than or equal to (≤) 50 milligrams (mg) within 4 weeks prior to planned
             randomization, or scheduled parenteral administrations during the study

          -  Joint(s) injected with intra-articular glucocorticoids or hyaluronic acid within 6
             weeks prior to planned randomization

          -  Active inflammatory diseases of the joints not related to RA

          -  Systemic autoimmune disease other than RA

          -  Juvenile idiopathic arthritis or juvenile RA and/or RA developed before the age of 16

          -  Active fibromyalgia that makes appropriate assessment of RA disease activity
             challenging in the opinion of the Investigator

          -  RA participants functional status class IV according to the ACR 1991 criteria

          -  Participants with severe chronic or recurrent viral, bacterial, parasitic, or fungal
             infections

          -  History of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human
             immunodeficiency virus (HIV) infection

          -  Any identified confirmed congenital or acquired immunodeficiency

          -  Abnormal laboratory values and liver function test

          -  Myocardial infarction within less than 6 months prior to participation in the study

          -  Severe central or peripheral nervous system diseases
Clinical trial NCT03003390 (phase 2, status: terminated)
Conditions: deep venous thrombosis
ICD codes: I81, K64.5, I51.3, I67.6, I74.11, I74.5, I74.8
Drugs: enoxaparin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    met protocol defined stopping rule for futility
  
Eligibility criteria:

        Inclusion Criteria

          1. Untunneled CVC inserted in the internal jugular or femoral vein within the past 24
             hours

          2. Child anticipated to stay in the pediatric intensive care unit ≥48 hours

          3. CVC anticipated to be required for ≥24 hours

          4. >36 weeks corrected gestational age to <18 years old

        Exclusion Criteria

          1. Coagulopathy (i.e., international normalized ratio >2.0, activated partial
             thromboplastin time >50 seconds or platelet count <50,000/mm3)

          2. Known bleeding disorder

          3. Clinically relevant bleeding as defined by the International Society on Thrombosis and
             Hemostasis (i.e., Hb decreased ≥2 g/dl in 24 hours, required medical or surgical
             intervention to restore hemostasis, or in a critical organ system [i.e.,
             retroperitoneum, pulmonary, intracranial or central nervous system])

          4. <60 days from a clinically relevant bleeding as defined above

          5. <7 days after trauma or surgery

          6. Anticipated surgery within 48 hours after insertion of the CVC

          7. Renal failure (i.e., creatinine clearance <30 mL/min)

          8. Presence of epidural catheter

          9. Currently taking an antithrombotic agent (e.g., low molecular weight heparin (LMWH),
             unfractionated heparin (UFH) at therapeutic doses, Coumadin or aspirin)

         10. Radiologically documented DVT at the site of insertion of the CVC in the previous 6
             weeks

         11. Known hypersensitivity to heparin or its components, including pork products

         12. History of heparin-induced thrombocytopenia (HIT) (i.e., positive serotonin release
             assay)

         13. Currently pregnant

         14. Currently lactating

         15. Prior enrollment in the study

         16. Limitation of care
Clinical trial NCT03003520 (phase 2, status: active, not recruiting)
Conditions: lymphoma, large b-cell, diffuse
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: durvalumab, rituximab, doxorubicin, vincristine, cyclophosphamide, prednisone, lenalidomide
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        Inclusion Criteria:

          1. CD20+Diffuse Large B-Cell Lymphoma.

          2. Ann Arbor stage 3 or 4 or stage 2 with bulky disease

          3. High or high-intermediate disease risk.

          4. No prior anti-lymphoma treatment.

          5. Subject is willing and able to undergo biopsy.

          6. Investigator considers R-CHOP immunochemotherapy appropriate.

          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

          8. Adequate hematology laboratory results (absolute neutrophil count ≥ 1.5 * 10^9/L,
             platelet count ≥ 75 * 10^9/L, hemoglobin ≥ 10.0 g/dL).

          9. Adequate biochemistry laboratory results (aspartate aminotransferase (AST/SGOT) and
             alanine aminotransferase (ALT/SGPT) ≤ 3.0 * upper limit of normal; bilirubin ≤ 2.0
             mg/dL; creatinine clearance of ≥ 40 mL/min).

         10. Bi-dimensionally measurable disease (> 2.0 cm).

         11. Subject is using effective contraception.

        Exclusion Criteria:

          1. Diagnosis of lymphoma other than Diffuse Large B-Cell Lymphoma.

          2. Composite lymphoma or transformed lymphoma.

          3. Primary or secondary Central Nervous System involvement by lymphoma.

          4. Seropositive or active viral infection with hepatitis B virus, human immunodeficiency
             virus or hepatitis C virus.

          5. History of other malignancies, unless disease-free for ≥ 5 years.

          6. Left ventricular ejection fraction < 50%.

          7. Peripheral neuropathy ≥ Grade 2.

          8. Prior use of lenalidomide, or monoclonal antibodies against CTLA-4, PD-1, or PD-L1.

          9. High risk of developing thromboembolic events, who are unwilling to take venous
             thromboembolism prophylaxis.

         10. Active or prior documented autoimmune or inflammatory disorders within the past 3
             years.

         11. Current or prior use of immunosuppressive medication within 28 days before start of
             treatment.
Clinical trial NCT03004638 (phase 2, status: completed)
Conditions: atherosclerosis, cardiovascular disease
ICD codes: I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83, A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30
Drugs: medi6012 40 mg, placebo, medi6012 120 mg, medi6012 300 mg, placebo iv push, medi6012 iv push
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Non-childbearing potential

          -  Diagnosis of stable atherosclerotic CVD

          -  Currently receiving a stable dose of Statin

        Exclusion Criteria:

          -  Unstable cardiovascular condition within 3 months of screening

          -  Elective arterial revascularization with in the past month

          -  Any planned arterial revascularization

          -  Body mass index <18 or >45

          -  Clinically significant ECG that may interfere with the interpretation of serial ECG
             and QT interval changes at screening

          -  Chronic kidney disease defined by estimated glomerular filtration rate of less than 30
             mL/mim/1.73m2

          -  Triglycerides greater than 500 mg/dL, LDL-C greater than 160 mg/dL, or HDL-C greater
             than 60 for males, or 65 for females

          -  Clinically significant vital sign abnormalities

          -  Genetic disorder of cholesterol metabolism

          -  History of overt liver disease

          -  Poorly controlled endocrine disorder (Diabetes or Thyroid disorder)

          -  Current or recent use of systemic corticosteroids

          -  Recent or ongoing infection or febrile illness

          -  History of active malignancy within 5 years

          -  History of alcohol or recreational substance abuse in the past 6 months

          -  Concurrent enrollment in another clinical study of any investigational drug therapy or
             use of any biologicals within 6 months prior to screening or within 5 half-lives of an
             investigational agent or biologic, whichever is longer.
Clinical trial NCT03005873 (phase 2, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: tlc599 ld group, normal saline, tlc599 hd group
SMILES: O
Eligibility criteria:

        Main Inclusion Criteria:

          1. Male or female patients, at least 50 years of age.

          2. Documented diagnosis of OA of the knee for at least 6 months

          3. The study knee has OA with Grade 2 to 3 severity based on the Kellgren Lawrence grades

          4. Patients with patient related visual analogue scale (VAS) score of 5.0 to 9.0 at
             baseline.

          5. Willing and able to comply with study procedures and provide written informed consent.

        Main Exclusion Criteria:

          1. Patients who received systemic corticosteroids within the last 30 days prior to
             dosing.

          2. Patients who use prohibited medications within 7 days prior to study drug
             administration or any pain control medication including acetaminophen within 48 hours
             prior to study drug administration.

          3. Patients who use prohibited medications other than acetaminophen and oral NSAIDs from
             screening visit to 7 days prior to study drug administration.

          4. Documented history and confirmed autoimmune disease

          5. History of post-traumatic knee arthritis, or evidence of intra articular bleeding of
             the study knee

          6. History of infective arthritis

          7. Unstable study knee joint

          8. Use of IA corticosteroid, hyaluronic acid, or other IA injection in the study knee
             within 3 months prior to the screening visit.

          9. A history of treated malignancy which is disease free for ≤ 5 years prior to the
             screening visit

         10. Uncontrolled and unstable concurrent medical or psychiatric illness, that will
             jeopardize the safety of the patient

         11. Use of any chemotherapeutic or systemic immunosuppressant agents for inflammatory
             diseases within 6 months prior to the screening visit.

         12. Current use of anticoagulants, including warfarin, heparin, low molecular weight
             heparin, or dabigatran.

         13. Abnormalities of laboratory parameters as described below will qualify for exclusion:

               -  hemoglobin < 8 g/dL;

               -  total white blood cell count < 4000/ µL;

               -  serum bilirubin/ alanine aminotransferase/ aspartate aminotransferase > 2 times
                  upper limit of normal (ULN) for the laboratory reference ranges;

               -  serum creatinine > 2 times ULN for the laboratory reference range;

               -  serum uric acid > ULN for the laboratory reference range;

               -  prothrombin time/International Normalized Ratio > ULN for the laboratory
                  reference range.

         14. Contraindication to undergoing magnetic resonance imaging (MRI)
Clinical trial NCT03011892 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: ruxolitinib cream, ruxolitinib cream, ruxolitinib cream, triamcinolone 0.1% cream, vehicle cream
SMILES: N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1, N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1, N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1, [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects diagnosed with atopic dermatitis as defined by the Hanifin and Rajka
             criteria.

          -  Subjects with a history of atopic dermatitis for at least 2 years.

          -  Subjects with an Investigator's Global Assessment score of 2 to 3 at screening and
             baseline.

          -  Subjects with body surface area of atopic dermatitis involvement, excluding the face
             and intertriginous areas, of 3% to 20% at screening and baseline.

          -  Subjects who agree to discontinue all agents used to treat atopic dermatitis from
             screening through the final follow-up visit.

        Exclusion Criteria:

          -  Subjects with evidence of active acute or chronic infections.

          -  Use of topical treatments for atopic dermatitis (other than bland emollients) within 2
             weeks of baseline.

          -  Systemic immunosuppressive or immunomodulating drugs (eg, oral or injectable
             corticosteroids, methotrexate, cyclosporine, mycophenolate mofetil, azathioprine)
             within 4 weeks or 5 half-lives of baseline (whichever is longer).

          -  Subjects with other dermatologic disease besides atopic dermatitis whose presence or
             treatments could complicate the assessment of disease (eg, psoriasis).

          -  Subjects with a history of other diseases besides dermatologic disorders (eg, other
             autoimmune diseases) taking treatments that could complicate assessments.

          -  Subjects with cytopenias at screening, defined as:

               -  Leukocytes < 3.0 × 10^9/L.

               -  Neutrophils < lower limit of normal.

               -  Hemoglobin < 10 g/dL.

               -  Lymphocytes < 0.8 × 10^9/L

               -  Platelets < 100 × 10^9/L.

          -  Subjects with severely impaired liver function (Child-Pugh Class C) or end-stage renal
             disease on dialysis or at least 1 of the following:

               -  Serum creatinine > 1.5 mg/dL.

               -  Alanine aminotransferase or aspartate aminotransferase ≥ 1.5 × upper limit of
                  normal.

          -  Subjects taking potent systemic cytochrome P450 3A4 inhibitors or fluconazole within 2
             weeks or 5 half-lives, whichever is longer, before the baseline visit (topical agents
             with limited systemic availability are permitted).

          -  Subjects who have previously received Janus kinase inhibitors, systemic or topical
             (eg, ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib).
Clinical trial NCT03018340 (phase 2, status: completed)
Conditions: adjunctive treatment of major depressive disorder
ICD codes: F25.1, F32.89, F33.8, F33.0, F33.1, F33.9, F32.0
Drugs: pimavanserin
SMILES: CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C2CCN(C)CC2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Adult patients, aged 18 years and above

          2. A clinical diagnosis of major depressive disorder (MDD)

          3. Is being treated with one of the following SSRI or SNRI antidepressants as
             monotherapy:

               -  Citalopram

               -  Escitalopram

               -  Paroxetine

               -  Fluoxetine

               -  Sertraline

               -  Duloxetine

               -  Venlafaxine

               -  Desvenlafaxine

               -  Venlafaxine XR

          4. Has a history of inadequate response to antidepressant treatments

        Exclusion Criteria:

          1. Patient has a psychotic disorder other than MDD

          2. Patient has current evidence of a serious and/or unstable neurologic, cardiovascular,
             respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder,
             including cancer or malignancies, which would affect the patient's ability to
             participate in the program

          3. Patient has a history or symptoms of long QT syndrome

        Patients will be evaluated at screening to ensure that all criteria for study participation
        are met. Patients may be excluded from the study based on these assessments (and
        specifically if it is determined that their baseline health and psychiatric condition do
        not meet all pre-specified entry criteria).
Clinical trial NCT03020004 (phase 2, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: danoprevir, ritonavir, peginterferon alfa-2a, ribavirin (rbv)
SMILES: CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1CC2=CC=CC(F)=C2C1)C(=O)NS(=O)(=O)C1CC1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Chronic HCV infection (≥ 6 months) ;

          -  Positive HCV antibody

          -  Serum HCV RNA of ≥ 1 × 104 IU/mL

          -  Hepatitis C virus GT1

          -  Never received prior-treatment for HCV with interferon, RBV, or other direct-acting or
             host-targeting antivirals for HCV

          -  The liver biopsy methods in the protocol (non-cirrhosis is defined as: Metavir score ˂
             4), or as determined by Fibroscan defined as: ˂ 14.6 kPa. Patients who have not
             obtained a liver biopsy or Fibroscan in the last 1 years will have a study related
             Fibroscan performed in order to confirm the diagnosis

          -  Others as specified in the detailed protocol

        Exclusion Criteria:

          -  Patients with Fibroscan detection value > 12.9 kPa, or histologic examination for
             liver cirrhosis patients

          -  Presence or history of non-hepatitis C chronic liver disease, including but not
             limited to, autoimmune hepatitis, α-1-antitrypsin deficiency, C282Y homozygous
             hemochromatosis, Wilson's disease, drug- or toxin-induced liver disease,
             alcohol-related liver disease, primary biliary cirrhosis, sclerosing cholangitis, and
             porphyria cutanea tarda causing liver pathology or requiring phlebotomy

          -  Patients with a history of liver cell cancer, screening before or screening suspected
             hepatocellular carcinoma (HCC) patients, or imaging studies found suspicious nodules,
             or AFP > 50 ng/mL

          -  Positive hepatitis A antibody，positive hepatitis B surface antigen，syphilis antibody
             or HIV antibody at screening

          -  Others as specified in the detailed protocol
Clinical trial NCT03022838 (phase 2/phase 3, status: terminated)
Conditions: migraine, caffeine withdrawal
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: caffeine
SMILES: CN1C=NC2=C1C(=O)N(C)C(=O)N2C
Reason stopped: 
    the study was terminated prematurely due to poor recruitment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  migraine present for at least 1 year and fulfilling diagnostic criteria (ICHD-3 beta)

          -  =/> 3 migraine attacks per month

          -  no migraine prophylaxis the last month

          -  consumption =/> 300 mg and </= 800 mg caffeine per day the last month

          -  signed consent

        Exclusion Criteria:

          -  suspicion of medication-overuse headache

          -  pregnancy and breast feeding

          -  serious co-morbidity or conditions requiring Medical treatment or caution

          -  working night shift

          -  use of drugs with moderate or major interactions with caffeine